US20070221213A1 - Dosage aerosols for the application of pharmaceutical formulations - Google Patents

Dosage aerosols for the application of pharmaceutical formulations Download PDF

Info

Publication number
US20070221213A1
US20070221213A1 US11/691,890 US69189007A US2007221213A1 US 20070221213 A1 US20070221213 A1 US 20070221213A1 US 69189007 A US69189007 A US 69189007A US 2007221213 A1 US2007221213 A1 US 2007221213A1
Authority
US
United States
Prior art keywords
amino
phenyl
quinazoline
methoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/691,890
Other languages
English (en)
Inventor
Herbert Wachtel
Hubert Hoelz
Marc Rohrschneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20070221213A1 publication Critical patent/US20070221213A1/en
Priority to US13/020,200 priority Critical patent/US9937306B2/en
Assigned to BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG reassignment BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WACHTEL, HERBERT, HOELZ, HUBERT, ROHRSCHNEIDER, MARC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/75—Aerosol containers not provided for in groups B65D83/16 - B65D83/74
    • B65D83/753—Aerosol containers not provided for in groups B65D83/16 - B65D83/74 characterised by details or accessories associated with outlets
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols

Definitions

  • the invention relates to pharmaceutical active substances, active substance mixtures and formulations for use as an aerosol in propellant-containing [1.1.1.2-tetrafluoroethane (HFC-134a) or 1.1.1.2.3.3.3-heptafluoropropane(HFC-227)] metered-dose aerosols and the metered-dose aerosols for administering these active substances, active substance mixtures and formulations.
  • propellant-containing 1.1.1.2-tetrafluoroethane (HFC-134a) or 1.1.1.2.3.3.3-heptafluoropropane(HFC-227)
  • aerosol formulations of medicaments by pressurised, dosage-measuring inhalers (MDIs, standing for “metered-dose inhalers”) is widespread in therapy, as in the treatment of asthma and diseases that cause obstruction of the airways. Compared with oral administration, inhalation results a faster onset of activity and at the same time reduces systemic side-effects to a minimum. Aerosol formulations can be administered by inhalation through the mouth or topically by application to the nasal mucosa.
  • Formulations for administering aerosol using MDIs may consist of solutions or suspensions.
  • Solution formulations have the advantage over suspension formulations that the pharmaceutical compositions are fully dissolved in the propellant and thus have a homogeneous nature. Solution formulations also avoid the problems associated with suspension formulations of physical instability and thus ensure the administration of equal doses for a longer period.
  • solution-type metered-dose aerosols generally do not require the addition of surfactants.
  • the propellant contains a mixture of chlorofluorocarbons (CFCs) to guarantee the desired properties of solubility, vapour pressure and stability of the formulation.
  • CFCs chlorofluorocarbons
  • the environmentally harmful CFC propellant present in aerosol inhalation formulations is being replaced by environmentally acceptable partly fluorinated hydrocarbon propellants (HFC propellants) or other non-chlorinated propellants.
  • the aim of the present invention is to provide a device with increased metering accuracy for the active substance, active substance mixture or formulation to prepare.
  • the mouthpiece tube of the device has a channel ( 8 ) which has no or almost no dead volume on its side remote from the metered-dose aerosol.
  • discharge volume is defined as the space which projects beyond the nozzle bore ( 9 ) and thus does not lie in the direct flow path.
  • FIG. 1 shows a mouthpiece tube with dead volume
  • FIG. 2 shows a mouthpiece tube with reduced dead volume
  • FIGS. 3 and 4 show a mouthpiece tube (the mouthpiece tube according to the invention in each case) with optimised reduction of the dead volume;
  • FIG. 5 shows a mouthpiece tube as in FIG. 1 a with reference numerals
  • the mouthpiece tube is a component with a number of functions:
  • the mouthpiece tube functionally consists of a shaft ( 2 ), a valve stem receptacle ( 5 ), a nozzle bore ( 9 ) and the mouthpiece ( 6 ).
  • the mouthpiece tube shaft ( 2 ) has the function of safely preventing canting of the valve stem ( 4 ) relative to the other valve components ( 3 ), which would be harmful to the valve ( 3 ), by restricting the room for movement of the metered-dose aerosol.
  • the valve stem receptacle ( 5 ) forms an abutment that limits the depth of immersion of the valve stem ( 4 ) in the stem receptacle of the mouthpiece tube.
  • the valve stem receptacle has a channel ( 8 ) which the actual nozzle bore ( 9 ) impacts upon at an obtuse angle to its perpendicular axis.
  • the nozzle bore has a diameter of 0.2-0.6 mm, preferably between 0.5-0.6 mm for suspension formulations and suslutions, as well as between 0.2-0.27 mm for solution formulations.
  • the active substance formulation which is liquefied under pressure can be deflected through >90° from the perpendicularly downwardly arranged opening of the valve stem ( 7 ) and pass outwards through the nozzle bore ( 9 ).
  • the spray cloud is finally generated at the transition from the nozzle bore ( 9 ) to the nozzle opening ( 10 ).
  • the alteration to the mouthpiece tube described in the invention is achieved by a substantially more exact positioning of the tool part comprising the nozzle pin and the core of the valve stem receptacle to one another by a conventional injection moulding process.
  • valve stems external diameter of the internal diameter of the valve Valve/manufacturer valve stem stem at the opening Bespak, BK357 3.17 ⁇ 0.01 mm 2.12 ⁇ 0.03 mm Valois, DF31/50RCU 3.19 ⁇ 0.01 mm 1.48 ⁇ 0.02 mm 3M, Neotechnic 2.76 ⁇ 0.01 mm 1.68 ⁇ 0.04 mm
  • the channel ( 8 ) is connected, via a nozzle bore ( 9 ), to a nozzle opening of funnel-shaped construction.
  • the device according to the invention is suitable for administering suitable active substance, or any suitable active substance mixture or formulation as single doses.
  • Examples of pharmaceutically effective active substances, active substance mixtures, or formulations include all the inhalable compounds, such as, e.g., inhalable macromolecules, as disclosed in EP 1 003 478.
  • inhalable compounds such as, e.g., inhalable macromolecules, as disclosed in EP 1 003 478.
  • active substances, active substance mixtures or formulations for the treatment of respiratory complaints which are taken by inhalation are used.
  • W is a pharmacologically active substance and is selected (for example) from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists, and PI3-kinase inhibitors.
  • W might be, for example:
  • the compounds used as betamimetics are preferably compounds selected from among albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulphonterol, terbutaline, tiaramide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248, and
  • the anticholinergics used are preferably compounds selected from among the tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active constituents.
  • the above-mentioned salts may preferably contain the chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions.
  • the chlorides, bromides, iodides, and methanesulphonates are particularly preferred.
  • X ⁇ denotes an anion with a single negative charge, preferably an anion selected from among the fluoride, chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, preferably an anion with a single negative charge, particularly preferably an anion selected from among the fluoride, chloride, bromide, methanesulphonate and p-toluenesulphonate, particularly preferably bromide, optionally in the form of the racemates, enantiomers or hydrates thereof.
  • corticosteroids it is preferable to use compounds selected from among beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR-106541, NS-126, ST-26, and
  • PDE4-inhibitors which may be used are preferably compounds selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofyllin, atizoram, D-4418, Bay-198004, BY343, CP-325.366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, and
  • the LTD4-antagonists used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 and
  • EGFR-inhibitors which may be used are preferably compounds selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62, and
  • the dopamine agonists used are preferably compounds selected from among bromocriptin, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, tergurid and viozan, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
  • these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • H1-Antihistamines which may be used are preferably compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine, and meclozine, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates, or hydrates thereof.
  • these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulphonate.
  • the compounds may come from the groups of ergot alkaloid derivatives, the triptans, the CGRP-inhibitors, the phosphodiesterase-V inhibitors, optionally in the form of the racemates, enantiomers, or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, the solvates, and/or hydrates thereof.
  • Examples of ergot alkaloid derivatives are dihydroergotamine and ergotamine.
  • suitable substances include pharmaceutical compositions, pharmaceutical formulations and mixtures with the above-mentioned active substances, as well as the salts and esters thereof and combinations of these active substances, salts, and esters.
  • the pharmaceutical preparation may additionally contain standard commercial suspension adjuvants, surfactants and/or stabilisers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
US11/691,890 2006-03-27 2007-03-27 Dosage aerosols for the application of pharmaceutical formulations Abandoned US20070221213A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/020,200 US9937306B2 (en) 2006-03-27 2011-02-03 Dosage aerosols for the application of pharmaceutical formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006014433 2006-03-27
DE102006014433A DE102006014433A1 (de) 2006-03-27 2006-03-27 Dosieraerosole für die Verabreichung von pharmazeutischen Zubereitungen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/020,200 Continuation US9937306B2 (en) 2006-03-27 2011-02-03 Dosage aerosols for the application of pharmaceutical formulations

Publications (1)

Publication Number Publication Date
US20070221213A1 true US20070221213A1 (en) 2007-09-27

Family

ID=38176097

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/691,890 Abandoned US20070221213A1 (en) 2006-03-27 2007-03-27 Dosage aerosols for the application of pharmaceutical formulations
US13/020,200 Active 2030-03-13 US9937306B2 (en) 2006-03-27 2011-02-03 Dosage aerosols for the application of pharmaceutical formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/020,200 Active 2030-03-13 US9937306B2 (en) 2006-03-27 2011-02-03 Dosage aerosols for the application of pharmaceutical formulations

Country Status (19)

Country Link
US (2) US20070221213A1 (ja)
EP (1) EP2001601B1 (ja)
JP (1) JP4903857B2 (ja)
KR (1) KR20080108141A (ja)
CN (1) CN101410189A (ja)
AR (1) AR060072A1 (ja)
AU (1) AU2007229531A1 (ja)
BR (1) BRPI0709198A2 (ja)
CA (1) CA2646612A1 (ja)
DE (1) DE102006014433A1 (ja)
EA (1) EA200801889A1 (ja)
EC (1) ECSP088732A (ja)
MX (1) MX2008011702A (ja)
NO (1) NO20083759L (ja)
PE (1) PE20071300A1 (ja)
TW (1) TW200815059A (ja)
UY (1) UY30241A1 (ja)
WO (1) WO2007110403A1 (ja)
ZA (1) ZA200807348B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080041387A1 (en) * 2004-03-05 2008-02-21 Boehringer Ingelheim International Gmbh Impaction nozzle for propellant driven metered dose aerosols
US20090020114A1 (en) * 2007-07-03 2009-01-22 Chiesi Farmaceutici S.P.A. Metered dose inhaler actuator
US20110186044A1 (en) * 2006-03-27 2011-08-04 Boehringer Ingelheim Pharma Gmbh &Co. Kg Dosage aerosols for the application of pharmaceutical formulations
JP2015071049A (ja) * 2008-07-11 2015-04-16 マップ・ファーマシューティカルズ・インコーポレイテッド エアロゾル薬物送達のためのコンテナ

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2781012A1 (en) * 2009-11-17 2011-05-26 Cipla Limited Inhalation solutions
US9227030B2 (en) * 2009-12-23 2016-01-05 Map Pharmaceuticals, Inc. Enhanced eductor design

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236418A (en) * 1962-11-16 1966-02-22 Oreal Apparatus for producing constant proportion mixtures of two or more aerosols
US3236457A (en) * 1963-08-21 1966-02-22 John R Kennedy Composite spray container assembly
US3367330A (en) * 1965-07-06 1968-02-06 Stanis A. Sierpin Aerosol type dispenser for fluids
US3383879A (en) * 1966-04-04 1968-05-21 Chill Master Corp Glass chiller
US3730437A (en) * 1970-06-19 1973-05-01 Ciba Geigy Corp Ejection device for multiple-product dispensers
US3920158A (en) * 1973-11-27 1975-11-18 Philip Meshberg Dual Dispensing valve
US4103684A (en) * 1976-12-30 1978-08-01 Aaron Ismach Hydraulically powered hypodermic injector with adapters for reducing and increasing fluid injection force
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4466838A (en) * 1978-11-15 1984-08-21 Hans Schwarzkopf Gmbh Pressurized carrier mixture for aerosol preparations
US4487334A (en) * 1980-08-06 1984-12-11 Werding Winfried J Thrust control means mountable in a pressurized container
US4681258A (en) * 1983-04-25 1987-07-21 National Research Development Corporation Producing directed spray
US4801465A (en) * 1987-04-20 1989-01-31 Sponer Richard A Dispenser apparatus for a solid particulate material and a fluid
US5054477A (en) * 1986-09-22 1991-10-08 Omron Tateisi Electronics Co. Nebulizer
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5249747A (en) * 1990-07-12 1993-10-05 Par-Way Group Sprayable dispensing system for viscous vegetable oils and apparatus therefor
US5301841A (en) * 1991-01-29 1994-04-12 Ing. Erich Pfeiffer Gmbh & Co. Kg Media discharge apparatus for housing a movable reservoir
US5358179A (en) * 1993-08-18 1994-10-25 The Procter & Gamble Company Atomization systems for high viscosity products
US5472143A (en) * 1992-09-29 1995-12-05 Boehringer Ingelheim International Gmbh Atomising nozzle and filter and spray generation device
US5524798A (en) * 1992-02-24 1996-06-11 Djs&T Limited Partnership Spray texturing nozzles having variable orifice
US5634571A (en) * 1995-06-07 1997-06-03 Innavision Services, Inc. Apparatus for dispensing two sprayable substances in a user selectable ratio
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
US6155251A (en) * 1997-03-28 2000-12-05 Kos Pharmaceuticals, Inc. Breath coordinated inhaler
US6357442B1 (en) * 1995-06-08 2002-03-19 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIS)
US20040079360A1 (en) * 1998-12-17 2004-04-29 Coffee Ronald Alan Nasal inhaler
US6737044B1 (en) * 1998-04-03 2004-05-18 University College Cardiff Consultants Limited Aerosol composition
US20040184994A1 (en) * 2003-03-20 2004-09-23 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20050274378A1 (en) * 2002-07-25 2005-12-15 Bonney Stanley G Medicament dispenser
US20060239930A1 (en) * 1997-08-04 2006-10-26 Herbert Lamche Process for nebulizing aqueous compositions containing highly concentrated insulin
US7195135B1 (en) * 1999-07-29 2007-03-27 Valois S.A.S Dispenser having a hinged dispensing head
US20080041387A1 (en) * 2004-03-05 2008-02-21 Boehringer Ingelheim International Gmbh Impaction nozzle for propellant driven metered dose aerosols

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994421A (en) 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
GB8917775D0 (en) * 1989-08-03 1989-09-20 Atomic Energy Authority Uk Aerosol inhaler
US5505192A (en) * 1993-11-12 1996-04-09 New-Med Corporation Dispenser monitoring system
GB9706121D0 (en) 1997-03-25 1997-05-14 Bespak Plc Inhalation device
GB2324121A (en) 1997-04-07 1998-10-14 Bespak Plc Seal arrangements for pressurised dispensing containers
DE19733651A1 (de) 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
KR20010072581A (ko) 1998-04-30 2001-07-31 캐롤린 에이. 베이츠 약품 에어로졸용 복용량 계량형 밸브
WO2000012162A1 (en) * 1998-08-28 2000-03-09 Glaxo Group Limited Dispenser
FR2791956B1 (fr) * 1999-04-12 2001-06-01 Oreal Tete de distribution pour dispositif du type a valve ou a pompe
AR026914A1 (es) * 1999-12-11 2003-03-05 Glaxo Group Ltd Distribuidor de medicamento
GB0026647D0 (en) 2000-10-31 2000-12-13 Glaxo Group Ltd Medicament dispenser
US7047964B2 (en) * 2001-01-25 2006-05-23 Clinical Designs Ltd. Dispenser for medicament
EP1321159A1 (en) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
US20060231093A1 (en) * 2002-11-04 2006-10-19 Simon Burge Pressurised inhalers
GB0322284D0 (en) * 2003-09-23 2003-10-22 Glaxo Group Ltd Medicament dispenser
JP4445966B2 (ja) * 2003-09-24 2010-04-07 メディ−ストリーム プロプライエタリィ リミティッド 薬物ホルダー
GB0328502D0 (en) * 2003-12-10 2004-01-14 3M Innovative Properties Co Metered dose dispensers and assemblies therefor
GB2417480B (en) * 2004-12-15 2006-08-02 Bespak Plc Improvements in or relating to valves
JP2008532567A (ja) * 2004-12-15 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 医療用エアロゾル装置に用いるエラストマーシール
DE102006014433A1 (de) 2006-03-27 2007-10-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dosieraerosole für die Verabreichung von pharmazeutischen Zubereitungen

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236418A (en) * 1962-11-16 1966-02-22 Oreal Apparatus for producing constant proportion mixtures of two or more aerosols
US3236457A (en) * 1963-08-21 1966-02-22 John R Kennedy Composite spray container assembly
US3367330A (en) * 1965-07-06 1968-02-06 Stanis A. Sierpin Aerosol type dispenser for fluids
US3383879A (en) * 1966-04-04 1968-05-21 Chill Master Corp Glass chiller
US3730437A (en) * 1970-06-19 1973-05-01 Ciba Geigy Corp Ejection device for multiple-product dispensers
US3920158A (en) * 1973-11-27 1975-11-18 Philip Meshberg Dual Dispensing valve
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4103684A (en) * 1976-12-30 1978-08-01 Aaron Ismach Hydraulically powered hypodermic injector with adapters for reducing and increasing fluid injection force
US4466838A (en) * 1978-11-15 1984-08-21 Hans Schwarzkopf Gmbh Pressurized carrier mixture for aerosol preparations
US4487334A (en) * 1980-08-06 1984-12-11 Werding Winfried J Thrust control means mountable in a pressurized container
US4681258A (en) * 1983-04-25 1987-07-21 National Research Development Corporation Producing directed spray
US5054477A (en) * 1986-09-22 1991-10-08 Omron Tateisi Electronics Co. Nebulizer
US4801465A (en) * 1987-04-20 1989-01-31 Sponer Richard A Dispenser apparatus for a solid particulate material and a fluid
US5249747A (en) * 1990-07-12 1993-10-05 Par-Way Group Sprayable dispensing system for viscous vegetable oils and apparatus therefor
US5301841A (en) * 1991-01-29 1994-04-12 Ing. Erich Pfeiffer Gmbh & Co. Kg Media discharge apparatus for housing a movable reservoir
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5524798A (en) * 1992-02-24 1996-06-11 Djs&T Limited Partnership Spray texturing nozzles having variable orifice
US5472143A (en) * 1992-09-29 1995-12-05 Boehringer Ingelheim International Gmbh Atomising nozzle and filter and spray generation device
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
US5358179A (en) * 1993-08-18 1994-10-25 The Procter & Gamble Company Atomization systems for high viscosity products
US5634571A (en) * 1995-06-07 1997-06-03 Innavision Services, Inc. Apparatus for dispensing two sprayable substances in a user selectable ratio
US6357442B1 (en) * 1995-06-08 2002-03-19 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIS)
US6155251A (en) * 1997-03-28 2000-12-05 Kos Pharmaceuticals, Inc. Breath coordinated inhaler
US20060239930A1 (en) * 1997-08-04 2006-10-26 Herbert Lamche Process for nebulizing aqueous compositions containing highly concentrated insulin
US6737044B1 (en) * 1998-04-03 2004-05-18 University College Cardiff Consultants Limited Aerosol composition
US20040079360A1 (en) * 1998-12-17 2004-04-29 Coffee Ronald Alan Nasal inhaler
US7195135B1 (en) * 1999-07-29 2007-03-27 Valois S.A.S Dispenser having a hinged dispensing head
US20050274378A1 (en) * 2002-07-25 2005-12-15 Bonney Stanley G Medicament dispenser
US20040184994A1 (en) * 2003-03-20 2004-09-23 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20080041387A1 (en) * 2004-03-05 2008-02-21 Boehringer Ingelheim International Gmbh Impaction nozzle for propellant driven metered dose aerosols

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080041387A1 (en) * 2004-03-05 2008-02-21 Boehringer Ingelheim International Gmbh Impaction nozzle for propellant driven metered dose aerosols
US7942146B2 (en) 2004-03-05 2011-05-17 Boehringer Ingelheim International Gmbh Impaction nozzle for propellant driven metered dose aerosols
US20110186044A1 (en) * 2006-03-27 2011-08-04 Boehringer Ingelheim Pharma Gmbh &Co. Kg Dosage aerosols for the application of pharmaceutical formulations
US9937306B2 (en) 2006-03-27 2018-04-10 Boehringer Ingelheim International Gmbh Dosage aerosols for the application of pharmaceutical formulations
US20090020114A1 (en) * 2007-07-03 2009-01-22 Chiesi Farmaceutici S.P.A. Metered dose inhaler actuator
JP2015071049A (ja) * 2008-07-11 2015-04-16 マップ・ファーマシューティカルズ・インコーポレイテッド エアロゾル薬物送達のためのコンテナ

Also Published As

Publication number Publication date
AR060072A1 (es) 2008-05-21
BRPI0709198A2 (pt) 2011-06-28
JP4903857B2 (ja) 2012-03-28
UY30241A1 (es) 2007-10-31
EP2001601B1 (de) 2014-05-14
WO2007110403A1 (de) 2007-10-04
EP2001601A1 (de) 2008-12-17
TW200815059A (en) 2008-04-01
CN101410189A (zh) 2009-04-15
EA200801889A1 (ru) 2009-04-28
PE20071300A1 (es) 2008-02-04
CA2646612A1 (en) 2007-10-04
MX2008011702A (es) 2008-09-24
NO20083759L (no) 2008-10-21
DE102006014433A1 (de) 2007-10-04
AU2007229531A1 (en) 2007-10-04
ZA200807348B (en) 2009-08-26
US9937306B2 (en) 2018-04-10
ECSP088732A (es) 2008-10-31
US20110186044A1 (en) 2011-08-04
JP2009531102A (ja) 2009-09-03
KR20080108141A (ko) 2008-12-11

Similar Documents

Publication Publication Date Title
US9682202B2 (en) Adapter, inhalation device, and atomizer
US9259540B2 (en) Nozzle and inhaler and method for producing a nozzle
US8733341B2 (en) Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
US7870856B2 (en) Inhaler
US8397717B2 (en) Inhaler with mouthpiece having a microbiological protective function
EP2326374B1 (en) Inhaler
US8196578B2 (en) Inhaler
US8518377B2 (en) Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US8205613B2 (en) Piston dosing pump
US20090277446A1 (en) Inhaler
US20100252032A1 (en) Inhaler
CA2653422A1 (en) Atomizer
US20100051023A1 (en) Inhaler
CA2653183A1 (en) Adapter with an attachment for an atomizer
US9533112B2 (en) Inhaler
US9937306B2 (en) Dosage aerosols for the application of pharmaceutical formulations
US20100059051A1 (en) Inhaler
US20110223113A1 (en) Propellant for dosing aerosols comprising packagings
US20070221535A1 (en) Package for multiple dose inhalators having optimised emptying properties
US20100186747A1 (en) Seal testing device

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WACHTEL, HERBERT;HOELZ, HUBERT;ROHRSCHNEIDER, MARC;SIGNING DATES FROM 20070423 TO 20070430;REEL/FRAME:043726/0991